Baxalta announced the launch of Adynovate (antihemophilic factor [recombinant], PEGylated), after receiving approval from the Food and Drug Administration (FDA) for on-demand treatment and control of bleeding episodes, and routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A aged ≥12 years.
Guidance relates to care team, resources committed to patient care, pediatric-specific techniques
In T2DM, also tied to increased triglycerides, aminotransferases, and liver fat content
Case report describes 87-year-old with 3 episodes; decreasing interval between dose, symptoms
Case report describes acyclovir-induced neurotoxicity in patient treated with recommended dose
Postoperative complications also increased in this patient population
Increased cost of building them is offset by decreases in additional medical care, research shows
Guidelines provided for physicians wishing to become more active in social media
The FDA has approved a sNDA for Linzess (linaclotide; Actavis and Ironwood) to allow the capsule contents to be sprinkled in applesauce or water for adults with swallowing difficulties. Also, the FDA has approved additional instructions for patients with nasogastric or gastric feeding tubes.
Children taking melatonin fell asleep about 21 minutes sooner than those taking placebo